1. Home
  2. CELC vs HNRG Comparison

CELC vs HNRG Comparison

Compare CELC & HNRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • HNRG
  • Stock Information
  • Founded
  • CELC 2011
  • HNRG 1949
  • Country
  • CELC United States
  • HNRG United States
  • Employees
  • CELC N/A
  • HNRG N/A
  • Industry
  • CELC Medical Specialities
  • HNRG Coal Mining
  • Sector
  • CELC Health Care
  • HNRG Energy
  • Exchange
  • CELC Nasdaq
  • HNRG Nasdaq
  • Market Cap
  • CELC 489.7M
  • HNRG 551.9M
  • IPO Year
  • CELC 2017
  • HNRG N/A
  • Fundamental
  • Price
  • CELC $12.86
  • HNRG $11.85
  • Analyst Decision
  • CELC Strong Buy
  • HNRG Strong Buy
  • Analyst Count
  • CELC 6
  • HNRG 2
  • Target Price
  • CELC $29.17
  • HNRG $15.00
  • AVG Volume (30 Days)
  • CELC 232.9K
  • HNRG 391.7K
  • Earning Date
  • CELC 11-14-2024
  • HNRG 11-12-2024
  • Dividend Yield
  • CELC N/A
  • HNRG N/A
  • EPS Growth
  • CELC N/A
  • HNRG N/A
  • EPS
  • CELC N/A
  • HNRG N/A
  • Revenue
  • CELC N/A
  • HNRG $429,359,000.00
  • Revenue This Year
  • CELC N/A
  • HNRG N/A
  • Revenue Next Year
  • CELC N/A
  • HNRG $7.22
  • P/E Ratio
  • CELC N/A
  • HNRG N/A
  • Revenue Growth
  • CELC N/A
  • HNRG N/A
  • 52 Week Low
  • CELC $11.51
  • HNRG $4.33
  • 52 Week High
  • CELC $22.19
  • HNRG $14.00
  • Technical
  • Relative Strength Index (RSI)
  • CELC 42.58
  • HNRG 48.06
  • Support Level
  • CELC $11.94
  • HNRG $11.31
  • Resistance Level
  • CELC $13.14
  • HNRG $13.83
  • Average True Range (ATR)
  • CELC 0.51
  • HNRG 0.65
  • MACD
  • CELC 0.07
  • HNRG -0.21
  • Stochastic Oscillator
  • CELC 58.70
  • HNRG 23.26

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About HNRG Hallador Energy Company

Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.

Share on Social Networks: